Light resistance training with pressure cuffs may reduce inflammation in older adults with muscle loss, similar to heavy weight training, which could help slow muscle decline.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether LRT-BFR consistently reduces systemic inflammation (IL-6, CRP) in older adults with sarcopenia compared to CRT or control, and whether changes correlate with muscle outcomes.
A systematic review and meta-analysis of all RCTs measuring IL-6, CRP, and TNF-α in adults ≥65 with AWGS-defined sarcopenia randomized to LRT-BFR (20–30% 1RM, 50% LOP), CRT (≥60% 1RM), or control over ≥12 weeks. Minimum 10 trials, 300+ participants, with correlation analysis between biomarker change and muscle mass/strength.
Whether LRT-BFR reduces systemic inflammatory biomarkers comparably to CRT in older adults with sarcopenia under controlled conditions.
A double-blind RCT with 150+ participants aged 65–85 with sarcopenia, randomized to LRT-BFR (3x/week, 20–30% 1RM, 50% LOP) or CRT (3x/week, 60–75% 1RM) for 24 weeks, with serum IL-6, CRP, and TNF-α measured at baseline, 12, and 24 weeks as primary endpoints.
Whether baseline or change in inflammatory biomarkers predicts rate of sarcopenia progression in older adults undergoing resistance training.
A prospective cohort study following 400 older adults with sarcopenia for 3 years, measuring serum IL-6 and CRP at baseline and annually, and tracking changes in ASMI and gait speed, adjusting for training exposure.
Whether older adults with sarcopenia and high inflammation have different responses to LRT-BFR compared to those with low inflammation.
A case-control study comparing 50 older adults with sarcopenia and high IL-6 (>5 pg/mL) to 50 with low IL-6 (<3 pg/mL), matched for age and baseline strength, assessing changes in muscle mass after 12 weeks of LRT-BFR.
Whether older adults with sarcopenia who currently perform LRT-BFR have lower inflammatory biomarkers than non-users.
A cross-sectional survey of 800 community-dwelling adults aged 65+ with sarcopenia, measuring current LRT-BFR use and serum IL-6, CRP, and TNF-α levels in a single assessment, adjusting for age, sex, and comorbidities.